Recursion Pharmaceuticals Trading Volume Drops 52.75% to $23.7 Million, Ranks 464th in Market

On July 22, 2025, Recursion Pharmaceuticals, Inc. (RXRX) saw a trading volume of $23.7 million, a 52.75% decrease from the previous day, ranking 464th in the day's stock market. The stock price increased by 2.19%, marking the fifth consecutive day of gains, with a total increase of 25.29% over the past five days.

Recursion Pharmaceuticals, Inc. has acquired full rights to REV102, a potential first-in-class oral ENPP1 inhibitor. This acquisition is a significant step for the company, as REV102 has shown promise in preclinical studies for treating various diseases, including cancer and metabolic disorders. The acquisition underscores Recursion's commitment to developing innovative therapies and expanding its pipeline of potential treatments.

This strategic move is expected to enhance Recursion's position in the biopharmaceutical industry, as it continues to focus on leveraging its proprietary technology platform to discover and develop novel drugs. The company's ability to identify and acquire promising compounds like REV102 demonstrates its dedication to advancing medical research and improving patient outcomes.